9084 Pemetrexed vs docetaxel as second-line in NSCLC: is there a difference between adenocarcinoma and squamous cell carcinoma? – a retrospective analysis of a single institution

I. Garassino, R. Cavina, C. Gandini, F. Cappuzzo, L. Giordano, D. Rahal, M. Roncalli, A. Santoro
  • European Journal of Cancer Supplements, September 2009, Elsevier
  • DOI: 10.1016/s1359-6349(09)71797-5

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1016/s1359-6349(09)71797-5

The following have contributed to this page: Dr Federico Cappuzzo